SYS-CON MEDIA Authors: Carmen Gonzalez, Liz McMillan, Elizabeth White, Pat Romanski, Kevin Jackson

News Feed Item

Erdosteine Received Orphan Drug Status by the FDA

MILAN, April 28, 2014 /PRNewswire/ --


Edmond Pharma is now looking for licensing partnership in Europe 

The Food and Drug Administration (FDA) has recently granted the Orphan Drug Status to Erdosteine​​, molecule discovered and developed by the R&D division of the Italian pharmaceutical company Edmond Pharma. The Orphan drug status refers to the new indication for the treatment of bronchiectasis, a rare disease for which no drug therapies are currently approved in the U.S. 

The molecule answers to an important unmet therapeutic need and it could reach remarkable performances. Indeed the potential for this treatment in the U.S. exceed 1 billion dollars. 

Today Erdosteine is marketed in over 40 countries worldwide for the treatment of various respiratory diseases, ranging from acute bronchitis to COPD. With a strong presence in Asia, Latin America and Estern Europe, today Edmond Pharma is looking for commercial licensing partnership in order to expand its presence in Europe.  

Milan, xxApril 2014 - Erdosteine, the most recent molecule developed in the class of mucus active drugs, discovered and developed by Edmond Pharma's research laboratories, has received the Orphan Drug Designation for the treatment of bronchiectasis by the FDA Office of Orphan Products Development (OOPD). The American regulatory Agency grants this status to drugs that can treat diseases affecting fewer than 200.000 patients in United States.

Already marketed in over 40 countries worldwide, for the treatment of acute and chronic bronchitis together with COPD, Erdosteine has started its registration process in U.S.

Considering the promising results for this new indication, Edmond Pharma is investing on further developments of the molecule and aims to build new partnership in Germany and France.

"We are very excited to have achieved, together with our U.S. partner Alitair Pharmaceuticals, the orphan drug status for Erdosteine​​®" says Roberto Teruzzi, CEO of Edmond Pharma and Corvette Group S.p.A. (holding company of the group). "This result represents a key milestone in our worldwide expansion. With our partners we extensively cover Asia, Middle East, Latin America and Eastern Europe and we are interested in newstrategicalliances for GermanyandFrance. The market potential of this new therapy in the United States is considerable, more than 1 billion dollars, and corresponds to a need of essential drug therapies, not completely satisfied. As a matter of fact there are no other drugs approved by the FDA for the treatment of bronchiectasis, a condition which has a heavy impact on the quality of life of the people affected".

Erdosteine​​ is now being used in studies targeted on bronchiectasis, conducted in the United States as part of the clinical development plan aimed to obtain the final marketing authorization of the product as orphan drug.

About Bronchiectasis 

Bronchiectasis is a condition characterized by irreversible dilation of the bronchial tree where the lungs produce an excessive quantity of mucus, which causes an obstruction of the airways resulting in proliferation of bacteria and recurrent infections. Impairing the airways' ability to move air in and out of the lungs, the disease can cause other serious health problems, such as dyspnea, atelectasis, and heart diseases, resulting in some cases even fatal. Today there are no therapies approved by the Food and Drug Administration to treat bronchiectasis.

About Erdosteine 

Erdosteine is a thiol, discovered in Italy in the Research and Development laboratories of Edmond Pharma, which, thanks to its muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant activities, is particularly effective in the treatment of respiratory diseases, such as Acute Bronchitis (AB), Chronic Bronchitis (CB) and Chronic Obstructive Pulmonary Disease (COPD). It modulates mucus production and viscosity and increases the motility of the mucociliary transport, improving expectoration. Its clinical efficacy, combined with an excellent safety profile, is proved by more than 3.000 patients treated in 60 clinical trials and by over ten year experience in clinical practice worldwide. Several studies on CB and COPD are currently ongoing in Europe, involving approximately 600 patients from 10 different countries.  

About Edmond Pharma Srl 

Edmond Pharma operates in three main business areas: production of active ingredients (APIs), finished pharmaceutical products and Erdosteine. Most of the APIs production is for export. Thanks to Erdosteine, Edmond Pharma is strongly involved in research and development in the respiratory field, it enters targeted partnership with leading pharmaceutical companies operating in this therapeutic area.

The company is controlled by Corvette Pharmaceutical Services Group SpA, parent company which provides high added value services to the pharmaceutical industry.

Additional information is available on the websites:

http://www.edmondpharma.com

http://www.erdosteine.net

For further information: 


Edmond Pharma S.r.l.
http://www.edmondpharma.it
http://www.erdosteine.net
Contact: Pierfrancesco Manzo
Erdosteine Sales and Business Development Director
+39-(0)2-95-00-46-283 | [email protected]

Press office

Contact: Marco Giorgetti, Antonella Martucci,
+39-(0)2-20-24-13-57 | [email protected]; [email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today Isomorphic Software, the global leader in high-end, web-based business applications, will exhibit at SYS-CON's DevOps Summit 2015 New York, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Isomorphic Software is the global leader in high-end, web-based business applications. We develop, market, and support the SmartClient & Smart GWT HTML5/Ajax platform, combining the productivity and performance of traditional desktop software ...
SYS-CON Media announced today that PagerDuty has launched a popular blog feed on DevOps Journal. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. DevOps Journal brings valuable information to DevOps professionals who are transforming the way enterprise IT is done.
Things are being built upon cloud foundations to transform organizations. This CEO Power Panel at 15th Cloud Expo, moderated by Roger Strukhoff, Cloud Expo and @ThingsExpo conference chair, addressed the big issues involving these technologies and, more important, the results they will achieve. Rodney Rogers, chairman and CEO of Virtustream; Brendan O'Brien, co-founder of Aria Systems, Bart Copeland, president and CEO of ActiveState Software; Jim Cowie, chief scientist at Dyn; Dave Wagstaff, VP ...
SYS-CON Events announced today that CodeFutures, a leading supplier of database performance tools, has been named a “Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9–11, 2015, at the Javits Center in New York, NY. CodeFutures is an independent software vendor focused on providing tools that deliver database performance tools that increase productivity during database development and increase database performance and scalability during production.
SYS-CON Events announced today that ActiveState, the leading independent Cloud Foundry and Docker-based PaaS provider, has been named “Silver Sponsor” of SYS-CON's DevOps Summit New York, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. ActiveState believes that enterprises gain a competitive advantage when they are able to quickly create, deploy and efficiently manage software solutions that immediately create business value, but they face many challenges that ...
Companies today struggle to manage the types and volume of data their customers and employees generate and use every day. With billions of requests daily, operational consistency can be elusive. In his session at Big Data Expo, Dave McCrory, CTO at Basho Technologies, will explore how a distributed systems solution, such as NoSQL, can give organizations the consistency and availability necessary to succeed with on-demand data, offering high availability at massive scale.
Today’s enterprise is being driven by disruptive competitive and human capital requirements to provide enterprise application access through not only desktops, but also mobile devices. To retrofit existing programs across all these devices using traditional programming methods is very costly and time consuming – often prohibitively so. In his session at @ThingsExpo, Jesse Shiah, CEO, President, and Co-Founder of AgilePoint Inc., discussed how you can create applications that run on all mobile ...
IoT is still a vague buzzword for many people. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. He also discussed how IoT is perceived by investors and how venture capitalist access this space. Other topics discussed were barriers to success, what is new, what is old, and what th...
Security can create serious friction for DevOps processes. We've come up with an approach to alleviate the friction and provide security value to DevOps teams. In her session at DevOps Summit, Shannon Lietz, Senior Manager of DevSecOps at Intuit, will discuss how DevSecOps got started and how it has evolved. Shannon Lietz has over two decades of experience pursuing next generation security solutions. She is currently the DevSecOps Leader for Intuit where she is responsible for setting and driv...
Dale Kim is the Director of Industry Solutions at MapR. His background includes a variety of technical and management roles at information technology companies. While his experience includes work with relational databases, much of his career pertains to non-relational data in the areas of search, content management, and NoSQL, and includes senior roles in technical marketing, sales engineering, and support engineering. Dale holds an MBA from Santa Clara University, and a BA in Computer Science f...
SYS-CON Media announced that Cisco, a worldwide leader in IT that helps companies seize the opportunities of tomorrow, has launched a new ad campaign in Cloud Computing Journal. The ad campaign, a webcast titled 'Is Your Data Center Ready for the Application Economy?', focuses on the latest data center networking technologies, including SDN or ACI, and how customers are using SDN and ACI in their organizations to achieve business agility. The Cisco webcast is available on-demand.
Thanks to Docker, it becomes very easy to leverage containers to build, ship, and run any Linux application on any kind of infrastructure. Docker is particularly helpful for microservice architectures because their successful implementation relies on a fast, efficient deployment mechanism – which is precisely one of the features of Docker. Microservice architectures are therefore becoming more popular, and are increasingly seen as an interesting option even for smaller projects, instead of bein...
Datapipe has acquired GoGrid, a provider of multi-cloud solutions for Big Data deployments. GoGrid’s proprietary orchestration and automation technologies provide 1-Button deployment for Big Data solutions that speed creation and results of new cloud projects. “GoGrid has made it easy for companies to stand up Big Data solutions quickly,” said Robb Allen, CEO, Datapipe. “Datapipe customers will achieve significant value from the speed at which we can now create new Big Data projects in the clou...
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. ...
Cloud Technology Partners on Wednesday announced it has been recognized by the Modern Infrastructure Impact Awards as one of the Best Amazon Web Services (AWS) Consulting Partners. Selected by the editors of TechTarget's SearchDataCenter.com, and by votes from customers and strategic channel partners, the companies acknowledged by the Modern Infrastructure Impact Awards represent the top providers of cloud consulting services for AWS including application migration, application development, inf...